Symon Z, Griffith K, Normolle D, McLaughlin PW, Sullivan M, Sandler HM: Dose
escalation for localized prostate cancer: Substantial benefit observed with
3D-conformal therapy. Int J Radiat Oncol Biol Phys 57:384-390, 2003.
Herman JM, Smith DC, Montie J, Hayman JA, Sullivan MA, Kent E, Griffith KA, Esper P, Sandler HM: Prospective quality of life (QOL) assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology 64:69-73, 2004.
Taylor JMG, Yu M, Sandler HM: Individualized predictions of disease progression following radiation therapy for prostate cancer. J Clin Oncol 23:816-825, 2005.
Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 65:965-974, 2006.
Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM: Measuring patients’ expectations regarding HRQOL outcomes associated with Prostate cancer surgery or radiotherapy. Urology 68:1224-1229, 2006.